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Dear Editor 
From late 2019 which Severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) was first 
diagnosed to now, about 31 million people have been 
diagnosed by coronavirus disease 2019 (COVID-19) 
and more than ninety-thousands people have been died, 
globally. Many antiviral medications have been 
evaluated for their effect on the virus life-cycle and 
some have been approved to be used in emergencies 
(1). To date, no effective agent has shown a definite 
effect in the pharmacotherapy of COVID-19. 
Although the optimal goal in this battle is to 
manufacture the vaccine, different aspects of the 
disease are now under investigation. Critical 
conditions due to ARDS and hyperinflammatory state 
play an important role in COVID-19 pathogenesis and 
it was shown in previous studies that mortality is 
increased in these patients (2). Hyperinflammation 
state in COVID-19, which leads to tissue damage and 
organ dysfunction, is caused by releasing a huge 
number of inflammatory mediators and is known as 
cytokine storm (3). The inhibitors of the immune-
mediated pathways are being strongly investigated due 
to their potential effect in the treatment of cytokine 
storm in severe COVID-19. 
Interleukin-1(IL-1) family contains 11 members 
with almost similar inflammatory activity (4). IL-1 
pathway, as a regulator cytokine in inflammation 
control other cytokines in innate immune response (5). 
IL-1 acts as a leukocytic pyrogen and induces fever and 
also enhances the acute phase response and increase 
the level of lymphocyte activation (6). Receptor and 
direct IL-1 inhibitors here are two main different types 
of IL-1 pathway blockers. Anakinra, the first approved 
agent, an IL-1 receptor antagonist which produce by 
recombinant technology and was first identified in 
urine samples of febrile patients and used to treat some 
immune-mediated diseases (7). It has been used safely 
in the treatment of inflammation related to septic shock 
syndromes such as acute respiratory distress syndrome 
(ARDS), subsequent hemophagocytic 
lymphohistiocytosis (HLH), and macrophage-
activating syndrome (MAS) and showed survival 
advantages (8). Based on clinical data on COVID-19, 
some clinical features of severe states are similar to 
HLH and MAS, but no in full similarity. In COVID-19 
hyper inflammation state, MAS due to persistent INF-
γ elevation which is an excessive inflammatory 
response is responsible for severe cytokine storm. 
There is some evidence for MAS/sHLH in COVID-19 
which is supported by the abnormal laboratory 
parameters. An increase in C-reactive protein and 
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hyperferritinaemia which both have been recorded in 
COVID-19 patients are two key parameters in 
MAS/HLD diagnosis. Hyperactivation of immune 
activity is more confined to the pulmonary parenchyma 
and is associated with the development of ARDS. An 
increase in IL-1 serum levels in cytokine panel in 
patients with severe COVID-19 which resemble 
MAS/HLH has been noted (9).  In this manner by 
inhibiting IL-1 pathway upregulation of multiple 
cytokines which is mediated by NF-κB reduced. 
From limited human study results on anakinra 
applicability in the treatment of moderate to severe 
COVID-19 patients with the hyperinflammatory state, 
some lights have been flashed. A cohort study in 
Milan, Italy confirmed COVID-19 patients with 
evidence of cytokine storm received different doses of 
anakinra by subcutaneous injection as an add-on 
therapy to hydroxychloroquine and lopinavir/ritonavir 
combination. Patients were followed to assess clinical 
outcomes on day 21. In this study treatment with high 
dose anakinra (5mg/kg) was associated with clinical 
improvement in 72% of the patients (10). 
Safety outcomes in the administration of 
immunomodulators to severe COVID-19 are so 
important. By inhibiting innate immune response, it 
could be possible that the rate of other co-infection and 
also, viremia due to SARS-CoV-2 increase. In 
previous studies, the safety profile of anakinra has been 
evaluated in a different situation. Anakinra showed a 
reliable safety profile and even in patients with sepsis 
could affect the mortality rate and high dose anakinra 
administration in moderate to severe non-ICU admitted 
patients have been used safely (10). Besides needed 
precautions due to the increase in infection risk or 
decrease in the neutrophil count by utilization of 
anakinra, others such as hypersensitivity reactions, 
drug accumulation in renal failure, and drug-drug 
interaction should be considered. 
Considering all the pros and cons of consuming 
anakinra as an IL-1 receptor blocker it may have an 
important role in decreasing the mortality or morbidity 
related to cytokine storm in SARS-CoV-2 infection. 
Currently, several trials have been conducted to assess 
the efficacy and safety of different doses of anakinra in 
COVID-19 (NCT04318366, NCT04364009) and by 
the results of these studies, more insight will be gained 
about the effect of IL-1 receptors blockers in the 
treatment of hyperinflammatory status related to 
COVID-19. 
 
Conflicts of Interest  
The authors declare that there are no conflicts of 
interest. 
 
References 
1. Ziaie S, Koucheck M, Miri M, Salarian S, Shojaei S, Haghighi M, 
et al. Review of therapeutic agents for the treatment of COVID-19. J 
Cell Mol Anesth. 2020;5(1):32-6. 
2 .Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of 
mortality due to COVID-19 based on an analysis of data of 150 
patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-8. 
3. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, 
Manson JJ. COVID-19: consider cytokine storm syndromes and 
immunosuppression. Lancet. 2020;395(10229):1033-4. 
4. Dinarello C, Arend W, Sims J, Smith D, Blumberg H, O'Neill L, et 
al. IL-1 family nomenclature. Nat Immunol. 2010;11(11):973. 
5. Dinarello CA. Immunological and inflammatory functions of the 
interleukin-1 family. Annu Rev Immunol. 2009;27:519-50. 
6. Dinarello CA. The interleukin-1 family: 10 years of discovery. 
FASEB J. 1994;8(15):1314-25. 
7. Liao Z, Grimshaw RS, Rosenstreich DL. Identification of a specific 
interleukin 1 inhibitor in the urine of febrile patients. J Exp Med. 
1984;159(1):126-36. 
8. Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika 
AN, et al. Therapeutic role of anakinra, an interleukin-1 receptor 
antagonist, in the management of secondary hemophagocytic 
lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage 
activating syndrome in critically ill children*. Pediatr Crit Care Med. 
2014;15(5):401-8. 
9. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of 
Cytokines including Interleukin-6 in COVID-19 induced Pneumonia 
and Macrophage Activation Syndrome-Like Disease. Autoimmun 
Rev. 2020;19(6):102537. 
10. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, 
Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in 
patients with COVID-19, acute respiratory distress syndrome, and 
hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 
2020;2(6):e325-e331. 
 
